[go: up one dir, main page]

MX2022010684A - Heterocyclic amides and their use for modulating splicing. - Google Patents

Heterocyclic amides and their use for modulating splicing.

Info

Publication number
MX2022010684A
MX2022010684A MX2022010684A MX2022010684A MX2022010684A MX 2022010684 A MX2022010684 A MX 2022010684A MX 2022010684 A MX2022010684 A MX 2022010684A MX 2022010684 A MX2022010684 A MX 2022010684A MX 2022010684 A MX2022010684 A MX 2022010684A
Authority
MX
Mexico
Prior art keywords
heterocyclic amides
modulating splicing
splicing
modulating
amides
Prior art date
Application number
MX2022010684A
Other languages
Spanish (es)
Inventor
Michael Walker Seiler
Dominic Reynolds
Anant A Agrawal
Frederic Vaillancourt
Peter Smith
Original Assignee
Remix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remix Therapeutics Inc filed Critical Remix Therapeutics Inc
Publication of MX2022010684A publication Critical patent/MX2022010684A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Replacement Of Web Rolls (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present disclosure features compounds of formula (l-a) and related compositions that, inter alia, modulate nucleic acid splicing e.g., splicing of a pre-mRNA, as well as methods of use thereof.
MX2022010684A 2020-02-28 2021-02-28 Heterocyclic amides and their use for modulating splicing. MX2022010684A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062983541P 2020-02-28 2020-02-28
US202063007333P 2020-04-08 2020-04-08
US202063040484P 2020-06-17 2020-06-17
US202063072790P 2020-08-31 2020-08-31
US202063126492P 2020-12-16 2020-12-16
PCT/US2021/020154 WO2021174165A1 (en) 2020-02-28 2021-02-28 Heterocyclic amides and their use for modulating splicing

Publications (1)

Publication Number Publication Date
MX2022010684A true MX2022010684A (en) 2023-01-19

Family

ID=75143749

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010684A MX2022010684A (en) 2020-02-28 2021-02-28 Heterocyclic amides and their use for modulating splicing.
MX2022010683A MX2022010683A (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022010683A MX2022010683A (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing.

Country Status (15)

Country Link
US (3) US20240190879A1 (en)
EP (3) EP4110785A1 (en)
JP (3) JP7736700B2 (en)
KR (2) KR20220159386A (en)
CN (2) CN115515679A (en)
AU (2) AU2021228767A1 (en)
BR (2) BR112022017188A2 (en)
CA (2) CA3169691A1 (en)
CL (2) CL2022002342A1 (en)
CO (2) CO2022013827A2 (en)
CR (2) CR20220484A (en)
IL (2) IL295956A (en)
MX (2) MX2022010684A (en)
SA (1) SA522440338B1 (en)
WO (3) WO2021174163A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7376471B2 (en) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド Compounds to treat Huntington's disease
KR102636383B1 (en) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for regulating splicing
CN114126613A (en) 2019-02-05 2022-03-01 斯基霍克疗法公司 Methods and compositions for modulating splicing
CN119638696A (en) 2019-02-06 2025-03-18 斯基霍克疗法公司 Methods and compositions for modulating splicing
EP4149937A1 (en) 2020-05-13 2023-03-22 CHDI Foundation, Inc. Htt modulators for treating huntington's disease
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
CA3230256A1 (en) 2021-08-30 2023-03-09 Dominic Reynolds Compounds and methods for modulating splicing
TW202319047A (en) 2021-08-30 2023-05-16 美商雷密克斯醫療公司 Compounds and methods for modulating splicing
CA3238090A1 (en) * 2021-11-17 2023-05-25 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
WO2023244996A2 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2024086569A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
AU2023365676A1 (en) 2022-10-17 2025-04-17 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2024182778A1 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2024182788A1 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202535379A (en) * 2024-01-26 2025-09-16 大陸商成都微芯藥業有限公司 Usp1 inhibitor and preparation method and use thereof
CN118166099B (en) * 2024-02-05 2024-10-22 北京大学深圳医院 Application of reagents for detecting hsa_circ_0014088 in the preparation of a kit for diagnosing oral squamous cell carcinoma

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4809656B2 (en) * 2005-09-29 2011-11-09 富士フイルム株式会社 Naphthalocyanine dye and method for producing the same
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
PL2049491T3 (en) * 2006-08-08 2011-04-29 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
US20100029657A1 (en) * 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
AU2009248774B2 (en) * 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
WO2010084067A2 (en) 2009-01-22 2010-07-29 Syngenta Participations Ag Insecticidal compounds
CA2762885A1 (en) * 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
CN102020643A (en) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 dihydropteridine ketone derivative, and preparation method and medicinal application thereof
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
PE20130376A1 (en) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8] NAPHTHYRIDINES SUBSTITUTED BY 2,4-DIARYLL AS KINASE INHIBITORS FOR USE AGAINST CANCER
JP2012028440A (en) 2010-07-21 2012-02-09 Hitachi Kokusai Electric Inc Substrate processing apparatus and method for manufacturing semiconductor device
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
MX336431B (en) * 2012-05-09 2016-01-18 Zoetis Services Llc Azetidine derivatives as antiparasitic agents.
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9675697B2 (en) * 2013-03-11 2017-06-13 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
KR20140125061A (en) * 2013-04-18 2014-10-28 (주)경인양행 An organoelectro luminescent compound and an organoelectroluminescent device using the same
RU2673542C2 (en) * 2013-06-25 2018-11-28 Ф. Хоффманн-Ля Рош Аг Compounds for treating spinal muscular atrophy
WO2015197503A1 (en) * 2014-06-25 2015-12-30 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016049524A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
CN104341403B (en) * 2014-10-10 2016-06-22 山东盛华电子新材料有限公司 A kind of 2,5-bis-heterocyclic substituted naphthyl alkane derivatives and preparation method thereof
NL2013636B1 (en) 2014-10-15 2016-10-04 Kraton Polymers Us Llc An accelerator system, a composition comprisng a synthetic isoprene polymer and the accelerator system, and dipped goods made from the composition.
JP6884102B2 (en) 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Compounds for the treatment of cancer
AU2016251253B2 (en) * 2015-04-24 2020-07-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
EA201800367A1 (en) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. METHODS OF TREATMENT OF HUNTINGTON'S DISEASE
US20190119236A1 (en) * 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP3544435A4 (en) 2016-11-28 2020-11-04 PTC Therapeutics, Inc. Methods for modulating rna splicing
EP3573954A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7376471B2 (en) * 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド Compounds to treat Huntington's disease
WO2018232039A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
KR102636383B1 (en) * 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for regulating splicing
EP3688187A4 (en) 2017-09-25 2021-09-29 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing modulators
CN111566102B (en) * 2017-10-18 2023-09-08 缆图药品公司 Substituted pyrrolopyridines as activin receptor-like kinase inhibitors
TW201942115A (en) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
WO2019199972A1 (en) 2018-04-10 2019-10-17 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
SI3814357T1 (en) 2018-06-27 2024-09-30 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
JOP20200338A1 (en) * 2018-06-27 2020-12-24 Reborna Biosciences Inc Preventive or treatment agent for spinal muscular atrophy
TWI834690B (en) * 2018-07-18 2024-03-11 美商富曼西公司 Isoxazoline compounds for controlling invertebrate pests
CN109180690A (en) * 2018-10-15 2019-01-11 烟台显华化工科技有限公司 One kind is used as azepine aromatic compound and its application of blue fluorescent material
CN119528824A (en) * 2018-12-10 2025-02-28 伊迪亚生物科学有限公司 2-Oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
WO2020132459A1 (en) * 2018-12-20 2020-06-25 The Regents Of The University Of Michigan Quinolinyl-pyrazine-carboxamide compounds and uses thereof
WO2020216190A1 (en) * 2019-04-22 2020-10-29 贝达药业股份有限公司 Quinazoline compound and pharmaceutical application thereof

Also Published As

Publication number Publication date
CR20220484A (en) 2022-12-15
CL2022002342A1 (en) 2023-03-17
JP7736700B2 (en) 2025-09-09
EP4110464A1 (en) 2023-01-04
AU2021228767A1 (en) 2022-09-29
CO2022013832A2 (en) 2022-10-31
CR20210483A (en) 2022-11-25
US20240226098A1 (en) 2024-07-11
JP2023515621A (en) 2023-04-13
US20230365566A1 (en) 2023-11-16
CN115515679A (en) 2022-12-23
JP2025172876A (en) 2025-11-26
SA522440338B1 (en) 2025-01-29
BR112022017188A2 (en) 2022-11-08
EP4110785A1 (en) 2023-01-04
KR20220158238A (en) 2022-11-30
IL295956A (en) 2022-10-01
BR112022017210A2 (en) 2022-10-25
IL295957A (en) 2022-10-01
EP4110459A1 (en) 2023-01-04
AU2021228284A1 (en) 2022-09-29
KR20220159386A (en) 2022-12-02
WO2021174164A1 (en) 2021-09-02
US20240190879A1 (en) 2024-06-13
CO2022013827A2 (en) 2022-10-31
CA3169691A1 (en) 2021-09-02
CA3169709A1 (en) 2021-09-02
MX2022010683A (en) 2023-01-19
CL2022002341A1 (en) 2023-03-10
CN115485025A (en) 2022-12-16
JP2023515620A (en) 2023-04-13
WO2021174165A1 (en) 2021-09-02
WO2021174163A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CR20220484A (en) Heterocyclic amides and their use for modulating splicing
MX2022012678A (en) Compounds and methods for modulating splicing.
WO2021207530A8 (en) Compounds and methods for modulating splicing
MX2022010681A (en) Compounds and methods for modulating splicing.
MX2022010637A (en) Pyridazine dervatives for modulating nucleic acid splicing.
PH12020551327A1 (en) Compounds
CR20210077A (en) New heterocyclic compounds as monoacylglycerol lipase inhibitors
MY201938A (en) Methods and compositions for modulating splicing
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX2020001833A (en) Pyruvate kinase modulators and use thereof.
MA47233A (en) AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS USED AS EHMT2 INHIBITORS AND THEIR METHODS OF USE
CL2017002883A1 (en) 2- (Phenyloxy or phenylthio) pyrimidine derivatives as herbicides
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
WO2019089442A8 (en) Aminoimidazopyridazines as kinase inhibitors
EA201001315A1 (en) HETEROCYCLIC INHIBITORS OF STEAROIL-CoA-DESATURASE
MX2021002509A (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1).
UY37647A (en) AMIDAS OF ACID N– (1,3,4 – OXADIAZOL – 2 – IL) SUBSTITUTED ARILCARBOXYL AND ITS COMPOUND AS HERBICIDES
MX2022014126A (en) Enpp1 modulators and uses thereof.
MX2023001558A (en) Compositions for modulating splicing.
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2024002554A (en) COMPOUNDS AND METHODS FOR MODULATING THE SPLICING.
WO2024182747A3 (en) Compounds and methods for modulating splicing
MX2024001899A (en) Potassium channel modulators.
MX2024002558A (en) COMPOUNDS AND METHODS FOR MODULAR SPLICING.
CR20220483A (en) Compounds and methods for modulating splicing